Octa, Stroke, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Conditions
Brief summary
Optical Coherence Tomography Angiography (OCTA) is a non-invasive tool that images the neurovascular structures of the eye by using near-infrared light. Previous literature has demonstrated the potential of OCTA as a screening tool in stroke, but its utility in other neurological illness such as intracranial hemorrhage is unclear. Hence, this pilot study will gather preliminary data to support future grant applications to investigate this area more fully by recruiting patients with neurological illness and healthy controls and comparing their OCTA imaging parameters.
Interventions
DEVICEOCTA
Optical Coherence Tomography Angiography
Sponsors
University of Texas Southwestern Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older * Patient admitted to the neuroscience intensive care unit with a diagnosis of: subarachnoid hemorrhage, intracerebral hemorrhage, intracranial aneurysm (ruptured or unruptured), intracranial vascular malformation, ischemic stroke, seizure disorder, intracranial infection, intracranial tumor(s), inflammatory demyelinating disease, traumatic brain injury and/or neuromuscular respiratory failure OR subjects from the community without major neurologic, cardiovascular, pulmonary or metabolic disease
Exclusion criteria
* Pregnancy * Non-English speaking * GCS motor score less than 6 (i.e. must be able to follow commands) * Temporary or permanent physical limitation that renders the patient unable to sit up and look inside OCTA device
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vascular and Perfusion Density in healthy controls | Once (approx. 10 mins) | Quantitative measure of retinal microperfusion. No definite time points are defined since different neurological diseases have different patterns of evolution and patient/provider availability may change. |
| Vascular and Perfusion Density in Patients with neurological disease | Throughout study completion up to 28 days | Quantitative measure of retinal microperfusion. No definite time points are defined since different neurological diseases have different patterns of evolution and patient/provider availability may change. |
Countries
United States
Contacts
Primary ContactNoah Jouett, DO, PhD
Backup ContactEmily Melikman, MBBS, RN
Outcome results
None listed